

CITATION REPORT

List of articles citing

Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing

DOI: 10.1097/jto.0000000000000493

Journal of Thoracic Oncology, 2015, 10, 844-851.

Source: <https://exaly.com/paper-pdf/60554019/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 85 | Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. <i>Cell</i> , 2015 , 163, 811-28 | 56.2 | 1185 |
| 84 | MST kinases in development and disease. <i>Journal of Cell Biology</i> , 2015 , 210, 871-82 | 7.3 | 100 |
| 83 | Hippo and TGF- β Interplay in the lung field. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015 , 309, L756-67 | 5.8 | 56 |
| 82 | Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 391 | 5 | 12 |
| 81 | Genetic Basis of Mesothelioma--More Than Asbestos Exposure. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e27-8 | 8.9 | 2 |
| 80 | Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. <i>Molecular Oncology</i> , 2016 , 10, 1255-65 | 7.9 | 27 |
| 79 | Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2016 , 19, 151-172 | 8.6 | 28 |
| 78 | Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells. <i>Cancer Gene Therapy</i> , 2016 , 23, 425-432 | 5.4 | 4 |
| 77 | MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e28-30 | 8.9 | 6 |
| 76 | Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. <i>Nature Genetics</i> , 2016 , 48, 407-16 | 36.3 | 497 |
| 75 | Hippo pathway deregulation: implications in the pathogenesis of haematological malignancies. <i>Journal of Clinical Pathology</i> , 2017 , 70, 9-14 | 3.9 | 1 |
| 74 | Targeting YAP in malignant pleural mesothelioma. <i>Journal of Cellular and Molecular Medicine</i> , 2017 , 21, 2663-2676 | 5.6 | 37 |
| 73 | Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome. <i>Oncology Reports</i> , 2017 , 38, 427-439 | 3.5 | 13 |
| 72 | Co-occurring Mutations of Tumor Suppressor Genes, and , in Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017 , 23, 3191-3202 | 12.9 | 50 |
| 71 | Novel insights into mesothelioma biology and implications for therapy. <i>Nature Reviews Cancer</i> , 2017 , 17, 475-488 | 31.3 | 199 |
| 70 | Drug development against the hippo pathway in mesothelioma. <i>Translational Lung Cancer Research</i> , 2017 , 6, 335-342 | 4.4 | 21 |
| 69 | Arrhythmogenic cardiomyopathy: Identification of desmosomal gene variations and desmosomal protein expression in variation carriers. <i>Experimental and Therapeutic Medicine</i> , 2018 , 15, 2255-2262 | 2.1 | 1 |

| | | | |
|----|--|------|-----|
| 68 | Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS. <i>Translational Oncology</i> , 2018 , 11, 268-274 | 4.9 | 13 |
| 67 | Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer. <i>Annual Review of Cancer Biology</i> , 2018 , 2, 59-79 | 13.3 | 13 |
| 66 | Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. <i>Journal of Thoracic Disease</i> , 2018 , 10, S342-S352 | 2.6 | 18 |
| 65 | Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1269-1283 | 8.9 | 54 |
| 64 | Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells. <i>Genes To Cells</i> , 2018 , 23, 606-613 | 2.3 | 7 |
| 63 | Genomics and Epigenetics of Malignant Mesothelioma. <i>High-Throughput</i> , 2018 , 7, | 4.3 | 28 |
| 62 | Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2018 , 19, | 6.3 | 10 |
| 61 | The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 2097-2106 | 4.9 | 8 |
| 60 | Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. <i>Cancers</i> , 2018 , 10, | 6.6 | 21 |
| 59 | YAP/TAZ Activation as a Target for Treating Metastatic Cancer. <i>Cancers</i> , 2018 , 10, | 6.6 | 87 |
| 58 | Presenilins as Drug Targets for Alzheimer's Disease-Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development. <i>International Journal of Molecular Sciences</i> , 2018 , 19, | 6.3 | 9 |
| 57 | Malignant Mesothelioma. 2018 , 259-281 | | |
| 56 | Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1704-1717 | 8.9 | 6 |
| 55 | Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 349 | 12.8 | 4 |
| 54 | The Hippo Signaling Pathway in Development and Disease. <i>Developmental Cell</i> , 2019 , 50, 264-282 | 10.2 | 254 |
| 53 | WW Domain-Containing Proteins YAP and TAZ in the Hippo Pathway as Key Regulators in Stemness Maintenance, Tissue Homeostasis, and Tumorigenesis. <i>Frontiers in Oncology</i> , 2019 , 9, 60 | 5.3 | 60 |
| 52 | The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 241-253 | 3.5 | 7 |
| 51 | Mesothelioma. 2019 , | | 1 |

| | | | |
|----|---|------|----|
| 50 | Regulation of TEAD Transcription Factors in Cancer Biology. <i>Cells</i> , 2019 , 8, | 7.9 | 81 |
| 49 | Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. <i>Journal of Physical Education and Sports Management</i> , 2019 , 5, | 2.8 | 5 |
| 48 | Mesothelium and Malignant Mesothelioma. <i>Journal of Developmental Biology</i> , 2019 , 7, | 3.5 | 16 |
| 47 | MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. <i>British Journal of Cancer</i> , 2019 , 120, 387-397 | 8.7 | 13 |
| 46 | Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. <i>Seminars in Cancer Biology</i> , 2020 , 61, 11-22 | 12.7 | 9 |
| 45 | Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 1087-1098 | 5.6 | 6 |
| 44 | Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920971421 | 5.4 | 15 |
| 43 | Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade. <i>Cancers</i> , 2020 , 12, | 6.6 | 3 |
| 42 | Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. <i>Journal of Experimental Medicine</i> , 2020 , 217, | 16.6 | 14 |
| 41 | A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations. <i>Frontiers in Oncology</i> , 2020 , 10, 928 | 5.3 | 25 |
| 40 | Identification of the RP11-21C4.1/SVEP1 gene pair associated with FAT2 mutations as a potential biomarker in gastric cancer. <i>Bioengineered</i> , 2021 , 12, 4361-4373 | 5.7 | 0 |
| 39 | Monoclonal Antibody JMAM-1 (Mouse Antihuman CD10) Against Malignant Mesothelioma. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021 , 40, 33 | 1.9 | |
| 38 | The tumor suppressor role of salvador family WW domain-containing protein 1 (SAV1): one of the key pieces of the tumor puzzle. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 1287-1297 | 4.9 | 1 |
| 37 | NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. <i>Cancers</i> , 2021 , 13, | 6.6 | 9 |
| 36 | Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of -deficient Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 986-998 | 6.1 | 18 |
| 35 | Precision Therapy for Mesothelioma: Feasibility and New Opportunities. <i>Cancers</i> , 2021 , 13, | 6.6 | 0 |
| 34 | Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 2 |
| 33 | The two sides of Hippo pathway in cancer. <i>Seminars in Cancer Biology</i> , 2021 , | 12.7 | 7 |

| | | | |
|----|--|------|----|
| 32 | Biological basis for novel mesothelioma therapies. <i>British Journal of Cancer</i> , 2021 , 125, 1039-1055 | 8.7 | 5 |
| 31 | Malignant Mesothelioma: Mechanism of Carcinogenesis. 2020 , 343-362 | | 2 |
| 30 | Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence. <i>Lung Cancer</i> , 2020 , 145, 85-94 | 5.9 | 10 |
| 29 | The NDR/LATS protein kinases in immunology and cancer biology. <i>Seminars in Cancer Biology</i> , 2018 , 48, 104-114 | 12.7 | 26 |
| 28 | Integrated analysis of long non-coding RNAs in human gastric cancer: An in silico study. <i>PLoS ONE</i> , 2017 , 12, e0183517 | 3.7 | 6 |
| 27 | Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. <i>Oncotarget</i> , 2016 , 7, 8321-31 | 3.3 | 35 |
| 26 | Loss of large tumor suppressor 1 promotes growth and metastasis of gastric cancer cells through upregulation of the YAP signaling. <i>Oncotarget</i> , 2016 , 7, 16180-93 | 3.3 | 47 |
| 25 | Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. <i>Oncotarget</i> , 2016 , 7, 28765-82 | 3.3 | 33 |
| 24 | Mesothelioma. 2016 , 8-70-8-71 | | |
| 23 | Clinical and biological implications of Hippo pathway dysregulation in sarcomas. <i>Forum of Clinical Oncology</i> , 2019 , 9, 11-16 | 0.3 | 1 |
| 22 | Unmet Needs and Future Outlook of Mesothelioma Management. 2019 , 331-340 | | |
| 21 | Molecular Pathology of Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021 , | 5.4 | 1 |
| 20 | The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. <i>American Journal of Cancer Research</i> , 2020 , 10, 4399-4415 | 4.4 | 7 |
| 19 | Presenilin1 inhibits glioblastoma cell invasiveness via promoting Sortilin cleavage. <i>Cell Communication and Signaling</i> , 2021 , 19, 112 | 7.5 | 1 |
| 18 | Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.. <i>Translational Lung Cancer Research</i> , 2022 , 11, 543-559 | 4.4 | |
| 17 | Advances in Drug Treatments for Mesothelioma.. <i>Expert Opinion on Pharmacotherapy</i> , 2022 , | 4 | 0 |
| 16 | The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non-small cell lung cancer.. <i>Thoracic Cancer</i> , 2022 , | 3.2 | 0 |
| 15 | EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: report of 3 cases in support of an emerging entity. <i>Genes Chromosomes and Cancer</i> , | 5 | 0 |

| | | | |
|----|--|-----|---|
| 14 | The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. <i>Current Oncology Reports</i> , | 6.3 | |
| 13 | Covalent Disruptor of YAP-TEAD Association Suppresses Defective Hippo Signaling. | | |
| 12 | Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer. <i>Thoracic Cancer</i> , | 3.2 | ○ |
| 11 | Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP. 2022 , 17, 407-431 | | ○ |
| 10 | A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities. 2022 , 243, 114684 | | 1 |
| 9 | What's Current and What's New in Mesothelioma?. 2022 , | | ○ |
| 8 | The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma. 2022 , 23, 13422 | | ○ |
| 7 | Discovery of a new class of reversible TEA-domain transcription factor inhibitors with a novel binding mode. 11, | | 1 |
| 6 | NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology. | | ○ |
| 5 | Roles of Hippo/YAP/TAZ signalling in intervertebral disc degeneration. 2023 , 159, 114099 | | ○ |
| 4 | Diseases of the Pleura. 2021 , 687-719 | | ○ |
| 3 | YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations. 2023 , 13, | | ○ |
| 2 | Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP/TEAD interaction and its potential as an anticancer agent. | | ○ |
| 1 | Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors. 2023 , 66, 4617-4632 | | ○ |